Target organ damage in African American hypertension: role of APOL1

Area of Science:

• Nephrology
• Genetics
• Hypertension Research

Background:

• Longstanding beliefs suggested essential hypertension significantly increases end-stage renal disease risk in African Americans.
• The African American Study of Kidney Disease and Hypertension provided new data challenging these assumptions.
• Apolipoprotein L1 (APOL1) gene variants are now recognized as key factors in kidney disease susceptibility.

Purpose of the Study:

• To re-evaluate the contribution of mild to moderate essential hypertension to end-stage renal disease in African Americans.
• To explore the role of APOL1 gene variants in various nephropathies.
• To identify novel therapeutic targets for APOL1-associated kidney diseases.

Main Methods:

• Analysis of APOL1 gene association studies.
• Review of data from the African American Study of Kidney Disease and Hypertension.
• Investigation of APOL1 variants in diverse kidney disease contexts, including hypertensive nephrosclerosis, FSGS, and HIV-associated nephropathy.

Main Results:

• APOL1 coding variants are directly implicated in a spectrum of kidney diseases, rather than solely hypertension.
• APOL1 nephropathy risk variants are maintained due to evolutionary protection against African sleeping sickness.
• These variants impact kidney transplant outcomes and aid in diagnosing nondiabetic nephropathy in diabetic African Americans.

Conclusions:

• APOL1 gene variants, not just hypertension, are central to kidney disease pathogenesis in African Americans.
• This discovery opens avenues for new treatments for specific patient groups, including those with low-level proteinuria.
• Understanding APOL1's role is crucial for addressing racial disparities in kidney disease and transplantation.